Critical Review: National Research (NRC) vs. Its Competitors

Share on StockTwits

National Research (NASDAQ: NRC) is one of 33 publicly-traded companies in the “Commercial physical research” industry, but how does it compare to its competitors? We will compare National Research to similar companies based on the strength of its dividends, institutional ownership, valuation, profitability, risk, analyst recommendations and earnings.

Insider & Institutional Ownership

36.0% of National Research shares are owned by institutional investors. Comparatively, 47.5% of shares of all “Commercial physical research” companies are owned by institutional investors. 4.5% of National Research shares are owned by insiders. Comparatively, 15.9% of shares of all “Commercial physical research” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares National Research and its competitors gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
National Research $119.69 million $30.05 million 59.18
National Research Competitors $1.17 billion $41.39 million 21.69

National Research’s competitors have higher revenue and earnings than National Research. National Research is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a summary of recent recommendations for National Research and its competitors, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
National Research 0 1 0 0 2.00
National Research Competitors 184 755 1572 73 2.59

As a group, “Commercial physical research” companies have a potential upside of 14.72%. Given National Research’s competitors stronger consensus rating and higher possible upside, analysts clearly believe National Research has less favorable growth aspects than its competitors.


National Research pays an annual dividend of $0.76 per share and has a dividend yield of 1.2%. National Research pays out 73.1% of its earnings in the form of a dividend. As a group, “Commercial physical research” companies pay a dividend yield of 1.2% and pay out 73.1% of their earnings in the form of a dividend.


This table compares National Research and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
National Research 24.59% 124.11% 28.56%
National Research Competitors -532.11% -25.20% -18.70%

Volatility & Risk

National Research has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500. Comparatively, National Research’s competitors have a beta of 3.32, suggesting that their average stock price is 232% more volatile than the S&P 500.


National Research competitors beat National Research on 9 of the 13 factors compared.

National Research Company Profile

National Research Corporation (NRC) is a provider of analytics and insights that facilitate revenue growth, patient, employee and customer retention and patient engagement for healthcare providers, payers and other healthcare organizations. The Company’s portfolio of subscription-based solutions provides information and analysis to healthcare organizations and payers across a range of mission-critical, constituent-related elements, including patient experience and satisfaction, community population health risks, workforce engagement, community perceptions, and physician engagement. The Company’s clients range from acute care hospitals and post-acute providers, such as home health, long term care and hospice, to numerous payer organizations. The Company derives its revenue from its annually renewable services, which include performance measurement and improvement services, healthcare analytics and governance education services.

Receive News & Ratings for National Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for National Research and related companies with's FREE daily email newsletter.